A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum.  As the discovery pipeline widens and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver cell-killing radioisotopes. One area that is showing considerable promise is the incorporation of an isotope-chelating moiety …Read More >

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway.  At AACR 2024, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin and concurrently expresses a membrane-bound …Read More >

Despite the success of delivery technologies such as lipid nanoparticles and trivalent GalNAc conjugation, targeted delivery of oligonucleotides to extra hepatic tissues remains a challenge.  At this year’s OPT Congress, WuXi AppTec presented a poster showing the utilization of our peptide-based DNA-encoded library screening platform to identify endocytosis receptor-binding peptides.  The binding affinity of hit …Read More >

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies, surrogate antibodies, diagnostic antibodies, therapeutic antibodies Antibody drug conjugate services, including site-specific conjugation Related antibody services, including peptide design and recombinant protein production

AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for Cancer Research (AACR) Annual Meeting 2024, one of the largest global cancer research conferences, will take place from April 5 to 10 at the San Diego Convention Center. This year, WuXi Biology has been selected …Read More >

What if a constructed PROTAC with a confirmed high-affinity warhead doesn’t work as expected? That means we need to take a closer, more careful look at how it’s designed and how it works. In this video, our expert from WuXi Biology shares strategies to address such an R&D scenario.

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we will discuss important trends …Read More >

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds.  At the SLAS 2024 meeting in Boston, WuXi AppTec presented a poster reporting on the assembly of a covalent fragment library that is suited to tackle protein targets via serine, lysine, and cysteine residues. In a case …Read More >